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Serial concentrations of pyrazinamide in 3 volunteers showed that increasing the dose
from 22 mg/kg of body-weight to 66 mg/kg resulted in substantially higher serum concen-
trations of the drug and a longer period of coverage (at a concentration of 25 µg/ml).
Similarly, in a. study based on 6 tuberculous patients, increasing the dose of pyrazinamide
from 66 mg/kg to 88 mg/kg led to appreciably higher concentrations in the serum. In neither
series of tests was any acute hepatic toxicity observed. The findings suggest that it would be
interesting to study the effect of doses of about 90 mg/kg of pyrazinamide in once-weekly
regimens of chemotherapy for the treatment of tuberculosis. 
Pyrazinamide, a potentially hepatotoxic drug, is
now usually administered in daily dosages of 20 to
40 mg/kg of body-weight since larger dosages had
proved toxic (McDermott et al., 1954; Morrissey &
Rubm, 1959; United States Public Health Service,
1959). However, at this Centre, the drug has been
given in dosages of 26 to 43 mg/kg of body-weight
daily without serious clinical toxicity (Velu et al.,
1961). In the course of planning a recent study at
the Centre, it was proposed to give pyrazinamide
(together with streptomycin and isoniazid) at once-
weekly intervals, and the feasibility of administering
higher doses of pyrazinamide was therefore consid-
ered. However, the administration of higher individ-
ual doses of pyrazinamide can be expected to in-
crease therapeutic efficacy only if it results in an
increase in the serum concentration of the drug. The
present study was therefore designed to provide
information on this subject.
PLAN AND CONDUCT OF THE INVESTIGATIONS
The investigations were undertaken in 2 stages. In
the first stage, 3 volunteers were each administered
3 doses of pyrazinamide, namely, 22 mg/kg of body-
weight, 44 mg/kg and 66 mg/kg, with at least 1 week
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between successive doses. Specimens of blood were
collected 1, 3, 6 and 24 hours after the administra-
tion of the drug. In the second stage, 6 patients
(whose pulmonary tuberculosis was under treatment
but whose chemotherapy did not include pyrazin-
amide) were each administered 2 doses of pyrazin-
amide, namely, 66 mg/kg of body-weight and
88 mg/kg, with an interval of 1 week between the
2 doses; specimens of blood were collected 3 and
6 hours after the administration of the drug.
The free pyrazinamide content of each specimen
of blood was estimated. In addition, in the study
involving patients, the serum L-aspartate: 2-oxoglu-
tarate aminotransferase (serum glutamic-oxaloacetic
transaminase; SGOT) activity of the 6-hour spe-
cimens was determined in order to detect any evi-
dence of acute liver toxicity.
METHODS
Estimation of pyrazinamide
The estimation of pyrazinamide was based on its
reaction with sodium nitritopentacyanoferroate.
Since pyrazinoic acid, a metabolite of pyrazinamide
with very little antituberculosis activity in vivo
(Kushner et al., 1952) or in vitro (Tuberculosis
Chemotherapy Centre, Madras, unpublished data)
also reacts with sodium nitritopentacyanoferroate,
it was removed by passing the serum sample
through a column of ion-exchange resin, and the
resulting eluate was used for the estimation of
pyrazinamide.
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Standards. Each batch of tests included the follow-
mg standards:
(1) Sheep serum blank (in duplicate);
(2) Standard solutions: sheep serum containing
20, 40, 80, 100 and 120 µg/ml pyrazinamide.
Procedure. A 1-ml sample of the test serum was
treated with 2 ml of 7.5 % trichloracetic acid and
then centrifuged at 3000g for 10 minutes; 1 ml of
the protein-free extract was then applied to a vertical
column (diameter 8 mm, height 40 mm) of Dowex-1-
8 chloride (200 to 400 mesh) prepared in water. The
column was repeatedly washed with small amounts
of water until two 5-ml eluates had been collected.
To each eluate, 0.5 ml of 2N NaOH and 0.5 ml of
nitritopentacyanoferroate reagent (Allen et al., 1953)
were added, and 10 minutes later, the intensity of the
resulting orange-brown complex was read in a Uni-
cam SP 600 spectrophotometer at 500 nm, using
cuvettes of 20 mm optical pathway. The sum of the
optical density (OD) readings for the 2 eluates
was regarded as the OD for the serum. (Eluate 1
usually contained the bulk of the pyrazinamide in
serum; thus, the mean OD of 60 test sera was
approximately 9 times higher for eluate 1 than for
eluate 2.) The same procedure was adopted for the
standard solutions and the blanks; a standard graph
was drawn and the pyrazinamide concentrations in
the teat sera were read off.
Estimation of SGOT
The SGOT activity was estimated by the procedure
described by the Sigma Chemical Company (1961),
and expressed in Karmen Units.
RESULTS
Concentrations of pyrazinamide in the serum
Volunteers. The serum concentrations of pyrazin-
amide produced in volunteers by different doses
of the drug are presented in Table 1 and summa-
rized in the upper half of Table 3. The mean concen-
trations at 1 hour were 19, 24 and 44 µg/ml with
the doses of 22, 44 and 66 mg/kg of body-weight,
respectively. A similar pattern was observed with,
the results at 3, 6 and 24 hours–namely, the mean
concentration being substantially higher with the
66 mg/kg dose than with the 22 mg/kg dose. Fur-
ther, with each of the 3 doses, the mean concentra-
tion was highest at 3 hours, being 27 µg/ml with
the 22 mg/kg dose, 52 µg/ml with the 44 mg/kg dose
and 70 µg/ml with the 66 mg/kg dose.
TABLE 1
SERUM CONCENTRATIONS OF PYRAZINAMIDE
IN VOLUNTEERS
Volunteer
1      74
2   61
3  75
24
11
22
2 1
1 3 6
22 45 38 31
44 65 59 55
66 48 76 59
22 2 1 36 31
44
66
22
44
66 29 48 54
7
11
16
Serum concentration of
Dose of pyrazinamide (µg/ml)
pyrazinamide after following number
( m g / k g )  of hours:
7
11
21
It is known that a large proportion of the bacterial
population in wild strains of tubercle bacilli is inhib-
ited in vitro by pyrazinamide in a concentration of
25 µg/ml (Tripathy, 1966). In this study, it was
estimated (from a graphical representation of the
data, which is not presented here) that this concen-
tration was attained after about 3 hours with the
22 mg/kg dose, after a little over 1 hour with the
44 mg/kg dose and under 1 hour with the 66 mg/kg
dose; these levels were maintained for approximately
4, 15 and 19 hours, respectively. Thus, increasing
the dose of pyrazinamide from 22 mg/kg to
66 mg/kg resulted in a longer period of coverage
with the drug.
All the 24-hour specimens contained pyrazinamide
in measurable quantities; further, the concentra-
tions with the 44 and 66 mg/kg doses were above
10 µg/ml in all 3 volunteers (Table 1). This suggests
that pyrazinamide persists in the body for a long
time and is metabolized slowly, an inference which is
confirmed by the finding that the half-life of the drug
(computed from the serum concentrations at 6 and
24 hours after the administration of the 66 mg/kg
dose) was approximately 12 hours for all 3 volun-
teers.
In summary, increasing the dose of pyrazmamide
from 22 mg/kg of body-weight to 66 mg/kg resulted
in higher serum concentrations of the drug between
1 and 24 hours, an approximately proportionate in-
crease in the highest concentration attained, and a
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TABLE 2
SERUM CONCENTRATIONS OF PYRAZINAMIDE
IN PATIENTS
Patient
1
2
3
4
5
6
Dose of
Weight       pyrazin-
mide    
(mg/kg)
34 66
88
38
40 66
88
36
43 66
68
50
Serum concentration of
pyrazinamide (µg/ml) at
the following number of
hours after administration
of the test dose:
3  6
9 1 94
142 170
109 95
107 113
81 70
129 138
63 72
59   121   
9 1 77
134 127
91 112
64 123
longer period of coverage with a concentration of
25 µg/ml.
Patients. The findings in patients are presented in
detail in Table 2, and summarized in the lower half
of Table 3. The mean concentrations at 3 and
6 hours were 86 µg/ml and 85 µg/ml with the 66 mg/kg
dose, and 105 µg/ml and 131 µg/ml, respectively,
TABLE 3
MEAN SERUM CONCENTRATION OF PYRAZINAMIDE IN
VOLUNTEERS AND IN PATIENTS
No. of
sub-
jects
Dose of
pyrazinamide
(mg/kg)
             22
Study in
volunteers 3 44
66
Mean serum concentra-
tion of pyrazinamide
(µg/ml) at
the following number
of hours after adminis-
tration of the test dose:
19
24
44
3  6
27 23
52 46
70 57
86 85
105 131
24
8
14
19
with the 88 mg/kg dose. Thus, the administra-
tion of a higher dose of pyrazinamide resulted in
appreciably higher mean serum concentrations of
the drug.
The mean serum concentrations at 3 and 6 hours
after the dose of 66 mg/kg of body-weight were
similar, suggesting that the drug was slowly ab-
sorbed and that the absorption continued beyond
3 hours. This is confirmed by the finding of a higher
mean concentration at 6 hours (131 µg/ml) than
at 3 hours (105 µg/ml) with the 88 mg/kg dose.
SGOT activity in patients
No acute hepatic toxicity was observed in any of
the 6 patients. Further, these patients had SGOT
values ranging from 21 to 40 units in the 6-hour
blood specimens collected after the first dose of
pyrazinamide, and from 29 to 45 units in similar
specimens collected after the second dose. These
values are within the ranges of 6 to 51 units (Tuber-
culosis Chemotherapy Centre, Madras, 1966) and 14
to 54 units (Ramakrishnan et al., 1968) l observed
in tuberculous patients on admission to treatment
at this Centre.
DISCUSSION
The estimation of pyrazinamide in biological
fluids is usually based on the reaction of the drug
with sodium nitritopentacyanoferroate in strongly
alkaline medium, giving an orange-brown complex
whose colour intensity can be determined spectro-
photometrically at a wavelength of 500 nm (Allen
et al., 1953; Caccia, 1957). Biological fluids contain-
ing pyrazinamide are likely to contain pyrazinoic
acid, a metabolite which also reacts with sodi-
um nitritopentacyanoferroate, producing a similar
colour complex. Estimates of pyrazinamide in bio-
logical fluids, based on its reaction with sodium
nitritopentacyanoferroate, would therefore indicate
the total content of pyrazinamide and pyrazinoic
acid. The latter has been shown to have very
little antituberculosis activity in mice (Kushner
et al., 1952) and in in vitro tests on Löwenstein-
Jensen medium and on acidified Löwenstein-Jensen
medium (Tuberculosis Chemotherapy Centre,
Madras, unpublished data). Consequently, a
method has been adopted which eliminates the pyra-
zinoic acid and estimates only the pyrazinamide
content of the serum.
1 See article on p. 775 of this issue.
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Our investigation with volunteers has shown that 22 mg/kg or 44 mg/kg of body-weight. Also, the
increasing the dose of pyrazinamide from 22 mg/kg absence of acute hepatic toxicity with the doses of
of body-weight to 66 mg/kg resulted in an ap- 66 mg/kg and 88 mg/kg in the study in patients is
proximately proportionate increase in the highest encouraging for the use of high-dosage pyrazinamide
pyrazinamide concentration attained, and in longer on a once-weekly basis. Finally, Ramakrishnan et
periods of coverage with a concentration of al. (1968) have shown that none of the 19 patients
25 µg/ml. Similarly, our study in patients has shown who received approximately 70 mg/kg of body-
that increasing the dose of pyrazinamide from weight of pyrazinamide on a once-weekly basis for
66 mg/kg of body-weight to 88 mg/kg resulted in 24 weeks had any evidence of hepatotoxicity. On the
appreciably higher serum concentrations. There is, basis of all these findings, a large-scale investigation
therefore, a pharmacological basis for expecting that of the efficacy of a once-weekly regimen of high-
pyrazinamide administered in doses of 66 mg/kg or dosage pyrazinamide plus high-dosage isoniazid plus
88 mg/kg of body-weight would be more effective streptomycin has been undertaken, the results of
therapeutically than when administered in doses of which will be reported later.
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La pyrazinamide est habituellement donnée à des doses Dans un deuxième stade, 6 malades atteints de tuber-
quotidiennes de 20 à 40 mg par kilogramme de poids culose pulmonaire ont reçu chacun 2 doses de 66 mg/kg
corporel. Envisageant de l’adrninistrer hebdomadaire- ou de 88 mg/kg de pyrazinamide à une semaine d’inter-
ment, en association avec la streptomycine et l’isoniazide, valle. Trois et 6 heures après la prise du produit, les
les auteurs ont étudié l’évolution des concentrations concentrations sériques moyennes ont atteint 86 et
sériques du produit en fonction des variations du dosage. 85 µg/ml dans le premier cas et 150 et 131 µg/ml lorsque
Dans un premier stade, trois volontaires ont reçu le dosage était porté à 88 mg/kg. Aucun signe d’hépato-
chacun 3 doses hebdomadaires successives de 22 mg/kg, toxicité aiguë n’a été observé chez ces 6 malades et les
44 mg/kg ou 66 mg/kg de pyrazinamide. Des échantil- valeurs de la transaminase glutamique-oxalacétique sont
lons de sang ont été prélevés 1, 3, 6 et 24 heures après restées dans des limites normales.
la prise du médicament. En portant la dose de 22 mg En raison de son intérêt thérapeutique et de son
à 66 mg/kg, on a obtenu des concentrations sériques plus innocuité, l’administration d’environ 90 mg/kg de pyra-
élevées entre la 1re et la 24e heure, une hausse approxi- zinamide dans les schémas de traitement hebdomadaire
mativement proportionnelle de la concentration maxi- mérite d’être envisagée. Des recherches à ce sujet sont
male et une persistance accrue de la concentration de actuellement en cours au Centre de chimiothérapie de
25 µg/ml. la tuberculose, à Madras, Inde.
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